Lilly’s Omvoh shows sustained 4-year efficacy in ulcerative colitis

Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis

Lupin launches partnership program to expand global reach of PrecisionSphere injectable platform

Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles

Hesperos and Bayer Consumer Health develop frst human-on-a-chip model of stress-induced cognitive dysfunction

New study presents a human-relevant stress model for assessing potential therapeutics

Celonic and Carbogen Amcis partner to deliver ADC development and manufacturing platform

Molcure and Boehringer Ingelheim team up to supercharge antibody discovery with AI

This collaboration aims to combine Molcure’s cutting-edge AI technology with Boehringer Ingelheim’s extensive expertise in drug discovery

Lonza expands cell and gene therapy portfolio

Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies

FDA supports new ANDA prioritization pilot to support US generic drugs

Takeda exits cell therapy research

Takeda will seek an external partner to leverage its cell therapy platform technologies

IPA welcomes Dr. Sharvil Patel as President and Glenn Saldanha as Vice President

Novartis to launch DTP platform for Cosentyx in US

Through the new DTP platform, Novartis will make Cosentyx available to patients at a price that reflects the average savings typically retained by insurers and pharmacy benefit managers